Ignite Creation Date:
2024-05-06 @ 1:37 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04070768
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-13
First Post:
2019-08-26
Brief Title:
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin GO and Venetoclax in Patients With Relapsed or Refractory CD33 Acute Myeloid LeukemiaBig Ten Cancer Research Consortium BTCRC-AML17-113
Sponsor:
John Quigley
Organization:
Big Ten Cancer Research Consortium
Organization Data
Organization:
Big Ten Cancer Research Consortium
Class:
OTHER
Study ID:
BTCRC-AML17-113
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
John Quigley
Lead Sponsor Class:
OTHER
Responsible Party:
John Quigley
Responsible Party Title:
Sponsor-Investigator
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Big Ten Cancer Research Consortium
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AbbVie | INDUSTRY |
| Pfizer | INDUSTRY |